NEW YORK--(BUSINESS WIRE)--Phosplatin Therapeutics today announced the appointment of José Jimeno, M.D., PhD as its Chief Medical Officer, effective May 1st, 2015.
Dr. Jimeno is best known for his leadership in the integrated development of Yondelis® (trabectedin), which is approved in 80 countries for the treatment of ovarian cancer and / or sarcoma. As Director of Clinical R&D, and later VP of Clinical and Scientific Development at PharmaMar (Madrid, Spain), Dr. Jimeno was also instrumental in licensing the US rights for Yondelis® to Janssen (Johnson and Johnson), and the Japan rights to Taiho Pharmaceutical, and in launching the respective developmental studies in the US and Japan. He was also involved in the development of Aplidine® (plitidepsin), which is currently completing a pivotal Phase III study for multiple myeloma. His previous drug development experience includes roles at Farmitalia Carlo Erba and US Biosciences, where he worked on the approval of agents in other drug classes, such as anthracyclines, hormone therapies, and antimetabolites. Most recently, Dr. Jimeno served as co-founder and CEO of Pangaea Biotech (Barcelona, Spain), a cancer diagnostics company focused on personalized medicine. Dr. Jimeno is the author of over 100 peer-reviewed articles on cancer research.
“We are very pleased to welcome Dr. José Jimeno to the Phosplatin Therapeutics family. He is a terrific collaborator and brings the ideal blend of medical and drug development insight to bear in our efforts to provide novel cancer therapies to patients and to the market. His success with Yondelis® and his enthusiasm for our lead agent, PT-112, bode well for our company’s first product,” noted Robert Fallon, Phosplatin’s President and Chief Executive Officer.
About Phosplatin Therapeutics
Phosplatin Therapeutics is a private pharmaceutical development company engaged in the development of phosphaplatins, a novel family of therapeutic compounds in oncology. The company’s work to date has been funded by private investors, with research initiatives in the United States, Europe and Asia. Its Phase I first-in-human study of PT-112 is ongoing with the Investigational Cancer Therapeutics group at The University of Texas MD Anderson Cancer Center in Houston, Texas, and at two other US sites, the Sarah Cannon Research Institute in Nashville, Tennessee, and the University of Colorado Cancer Center in Aurora, Colorado. Visit: www.phosplatin.com